Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptivus "Suboptimal" Comparator Arm Likely Key Issue For Antivirals Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

The majority of comparator patients in the pivotal RESIST trials were resistant to their assigned agent, FDA says. The agency's reanalysis of the trials, however, continues to show statistical significance for tipranavir. Safety issues for Boehringer Ingelheim's HIV drug include hepatotoxicity and drug-drug interactions.

You may also be interested in...



Aptivus Needs Further Studies To Guide Use After Accelerated Approval, Cmte. Says

More information is needed on appropriate HIV patient populations and how to manage adverse events, FDA's Antiviral Drugs Advisory Committee says. Accelerated approval is recommended by 11-to-3 vote for use of Boehringer Ingelheim's tipranavir in heavily pre-treated patients.

Aptivus Needs Further Studies To Guide Use After Accelerated Approval, Cmte. Says

More information is needed on appropriate HIV patient populations and how to manage adverse events, FDA's Antiviral Drugs Advisory Committee says. Accelerated approval is recommended by 11-to-3 vote for use of Boehringer Ingelheim's tipranavir in heavily pre-treated patients.

Boehringer Ingelheim Aptivus To Get FDA Advisory Committee Review In May

Tipranavir will be considered by FDA's Antiviral Drugs Advisory Committee for the treatment of patients with multi-drug-resistant HIV. In clinical trials, use of the protease inhibitor was associated with GI adverse events and elevated triglycerides.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel